ICU Medical (NASDAQ:ICUI) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $8.45-8.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.60. ICU Medical also updated its FY18 guidance to $8.45-8.85 EPS.

ICU Medical stock opened at $232.01 on Friday. ICU Medical has a 52 week low of $196.33 and a 52 week high of $321.70. The stock has a market cap of $5.31 billion, a P/E ratio of 35.99 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, November 8th. The medical instruments supplier reported $1.85 EPS for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.34. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The firm had revenue of $327.20 million during the quarter, compared to the consensus estimate of $334.97 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue was down 4.7% compared to the same quarter last year. Analysts expect that ICU Medical will post 7.6 EPS for the current fiscal year.

ICUI has been the subject of a number of research reports. ValuEngine downgraded ICU Medical from a strong-buy rating to a buy rating in a report on Friday, August 3rd. Zacks Investment Research raised ICU Medical from a hold rating to a strong-buy rating and set a $337.00 target price for the company in a report on Wednesday, August 15th. TheStreet raised ICU Medical from a c+ rating to a b+ rating in a report on Monday, August 20th. Finally, BidaskClub downgraded ICU Medical from a strong-buy rating to a buy rating in a report on Thursday, September 20th.

In other ICU Medical news, VP Thomas D. Mccall sold 11,133 shares of the business’s stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $302.56, for a total value of $3,368,400.48. Following the completion of the transaction, the vice president now directly owns 3,018 shares of the company’s stock, valued at $913,126.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 787 shares of the business’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the completion of the transaction, the vice president now directly owns 1,367 shares of the company’s stock, valued at $414,365.04. The disclosure for this sale can be found here. Insiders have sold 711,920 shares of company stock valued at $202,651,956 in the last ninety days. Corporate insiders own 12.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ICU Medical (ICUI) Updates FY 2018 Earnings Guidance” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://theolympiareport.com/2018/11/10/icu-medical-icui-updates-fy-2018-earnings-guidance.html.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Read More: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.